NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer
FORT WORTH, Texas–(BUSINESS WIRE)–NanOlogy LLC, a clinical-stage interventional oncology drug company, announced today that results from a clinical trial of Large Surface Area Microparticle Docetaxel (LSAM-DTX) in High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) have been published in The Journal of Urology®. The research article entitled Phase 1/2 Trial Results of a Large Surface Area Microparticle … [Read more…]
